Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Prevail expects to initiate enrollment in Phase 1/2 PROCLAIM trial in Q4 » 07:18
11/13/20
11/13
07:18
11/13/20
07:18
PRVL

Prevail Therapeutics

$9.72 /

-0.01 (-0.10%)

Phase 1/2 PROCLAIM Trial…

Phase 1/2 PROCLAIM Trial Expected to Initiate Enrollment in Fourth Quarter of 2020: Initiation of patient enrollment remains on track for the fourth quarter of 2020 for the Phase 1/2 PROCLAIM clinical trial of PR006 for frontotemporal dementia with GRN mutations. The optimized immunosuppression regimen used in the amended PROPEL trial will also be implemented in the PROCLAIM trial. The Company currently anticipates it will provide a biomarker and safety analysis on a subset of patients in the PROCLAIM trial in 2021.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

Hot Stocks
Prevail expects to initiate enrollment in Phase 1/2 PROVIDE trial in Q4 » 07:17
11/13/20
11/13
07:17
11/13/20
07:17
PRVL

Prevail Therapeutics

$9.72 /

-0.01 (-0.10%)

Phase 1/2 PROVIDE Trial…

Phase 1/2 PROVIDE Trial Expected to Initiate Enrollment in Fourth Quarter of 2020: Initiation of patient enrollment remains on track for the fourth quarter of 2020 for the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease. The optimized immunosuppression regimen used in the amended PROPEL trial will also be implemented in the PROVIDE trial. The Company currently anticipates it will provide the next update on PR001 biomarker and safety data for neuronopathic Gaucher disease in 2021.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

Hot Stocks
Prevail expects biomarker, safety analysis in PROPEL trial by mid-2021 » 07:17
11/13/20
11/13
07:17
11/13/20
07:17
PRVL

Prevail Therapeutics

$9.72 /

-0.01 (-0.10%)

Patient Dosing Continues…

Patient Dosing Continues in Phase 1/2 PROPEL Trial of PR001 for Parkinson's disease with GBA1 mutations: Enrollment in the Phase 1/2 PROPEL clinical trial for PD-GBA has resumed following implementation of modifications to the clinical protocol. As previously announced, Prevail elected to modify the immunosuppression regimen in the clinical protocol for PROPEL and has adapted the trial design to be open-label. The Company expects to provide the next biomarker and safety analysis on a subset of patients in the PROPEL trial by mid-2021.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

Hot Stocks
Prevail Therapeutics expects cash runway to extend into 1H22 » 07:16
11/13/20
11/13
07:16
11/13/20
07:16
PRVL

Prevail Therapeutics

$9.72 /

-0.01 (-0.10%)

Cash, cash equivalents…

Cash, cash equivalents and investments were $114.3 million as of September 30, 2020, as compared to $131.2 million and $168.1 million as of June 30, 2020 and December 31, 2019, respectively. The Company continues to anticipate that its cash runway will extend into the first half of 2022.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

Earnings
Prevail Therapeutics reports Q3 EPS (55c), consensus (65c) » 07:15
11/13/20
11/13
07:15
11/13/20
07:15
PRVL

Prevail Therapeutics

$9.72 /

-0.01 (-0.10%)

"We're pleased…

"We're pleased to be making significant progress across our pipeline as we seek to develop urgently needed disease-modifying gene therapy treatments for patients with neurodegenerative diseases," said Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail. "We are encouraged by the continuation of patient dosing in our Phase 1/2 PROPEL trial of PR001 for Parkinson's disease with GBA1 mutations, and we are excited to advance our PROVIDE and PROCLAIM clinical trials for Type 2 Gaucher disease and frontotemporal dementia with GRN mutations, respectively, this year."

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

PRVL Prevail Therapeutics
$9.72 /

-0.01 (-0.10%)

Hot Stocks
Alector awarded damages for breach of consulting agreement with Asa Abeliovich » 07:51
11/02/20
11/02
07:51
11/02/20
07:51
ALEC

Alector

$9.42 /

-0.1 (-1.05%)

, PRVL

Prevail Therapeutics

$9.80 /

-0.15 (-1.51%)

Alector (ALEC) announced…

Alector (ALEC) announced that an independent arbitrator issued an interim, confidential decision in favor of the company in its dispute with Asa Abeliovich, M.D., Ph.D., founder and CEO of Prevail Therapeutics (PRVL). The company said, "The arbitrator found Dr. Abeliovich liable for breach of his consulting agreement with Alector and for spoliation based on his destruction of documents relevant to the proceeding. The arbitrator awarded damages for breach of the agreement, and sanctions for the spoliation as well as violation of orders during the proceeding. The monetary amounts of the damages and sanctions will be determined in further proceedings." In June 2019, Alector initiated a confidential arbitration proceeding against Dr. Abeliovich, its former co-founder and consulting chief scientific officer and chief innovation officer, related to alleged breaches of his consulting agreement and the improper use of confidential information he obtained during the course of providing services for the company.Details relating to the arbitration proceeding and its outcome are confidential.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

06/24/20 H.C. Wainwright
Alector initiated with a Buy at H.C. Wainwright
04/28/20 Goldman Sachs
Alector initiated with a Buy at Goldman Sachs
03/06/20 Citi
Citi starts Alector at Buy, recommends for dementia space exposure
03/05/20 Citi
Alector initiated with a Buy at Citi
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

  • 15
    Jul
  • 30
    Jan
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

Hot Stocks
Prevail Therapeutics announces victory in arbitration brought by Alector » 07:18
11/02/20
11/02
07:18
11/02/20
07:18
PRVL

Prevail Therapeutics

$9.80 /

-0.15 (-1.51%)

, ALEC

Alector

$9.42 /

-0.1 (-1.05%)

Prevail Therapeutics…

Prevail Therapeutics (PRVL) announced a victory in the arbitration proceeding brought in 2019 by Alector (ALEC) against Prevail's founder and CEO Asa Abeliovich, M.D., Ph.D. The arbitrator rejected all of Alector's principal claims against Dr. Abeliovich, including all claims alleging misappropriation or misuse of trade secrets. Significantly, the arbitrator rejected Alector's claims that Dr. Abeliovich used Alector trade secrets or confidential information in connection with his work on behalf of Prevail, as well as Alector's claim that it has rights to Prevail's patents and patent applications. Prevail was not a party to this arbitration. The only relief granted to Alector by the arbitrator was permission to seek reimbursement for a portion of Alector's out-of-pocket costs and fees in connection with certain document retention-related claims. Alector will need to provide sufficient proof of such amounts.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
ALEC Alector
$9.42 /

-0.1 (-1.05%)

06/24/20 H.C. Wainwright
Alector initiated with a Buy at H.C. Wainwright
04/28/20 Goldman Sachs
Alector initiated with a Buy at Goldman Sachs
03/06/20 Citi
Citi starts Alector at Buy, recommends for dementia space exposure
03/05/20 Citi
Alector initiated with a Buy at Citi
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

  • 15
    Jul
  • 30
    Jan
PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

ALEC Alector
$9.42 /

-0.1 (-1.05%)

PRVL Prevail Therapeutics
$9.80 /

-0.15 (-1.51%)

Hot Stocks
Prevail Therapeutics receives FDA Fast Track designation for PR001 » 07:20
10/27/20
10/27
07:20
10/27/20
07:20
PRVL

Prevail Therapeutics

$10.45 /

-0.39 (-3.60%)

Prevail Therapeutics…

Prevail Therapeutics announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company's experimental gene therapy program, PR001, for the treatment of neuronopathic Gaucher disease. The Company expects to initiate enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 for Type 2 neuronopathic Gaucher disease patients in the second half of 2020. The FDA previously granted PR001 Rare Pediatric Disease Designation for the treatment of nGD, and Orphan Drug Designation for the treatment of patients with Gaucher disease. In addition, the FDA has granted Fast Track designation for PR001 for the treatment of Parkinson's disease with GBA1 mutations.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

Conference/Events
Prevail Therapeutics management to meet virtually with Oppenheimer » 04:55
10/27/20
10/27
04:55
10/27/20
04:55
PRVL

Prevail Therapeutics

$10.45 /

-0.39 (-3.60%)

Virtual Meeting to be…

Virtual Meeting to be held on October 27 hosted by Oppenheimer.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

PRVL Prevail Therapeutics
$10.45 /

-0.39 (-3.60%)

Over a month ago
Conference/Events
Prevail Therapeutics management to meet virtually with Oppenheimer » 12:16
10/20/20
10/20
12:16
10/20/20
12:16
PRVL

Prevail Therapeutics

$10.00 /

+0.25 (+2.56%)

Virtual Meeting to be…

Virtual Meeting to be held on October 27 hosted by Oppenheimer.

ShowHide Related Items >><<
PRVL Prevail Therapeutics
$10.00 /

+0.25 (+2.56%)

PRVL Prevail Therapeutics
$10.00 /

+0.25 (+2.56%)

09/14/20 William Blair
Prevail Therapeutics initiated with an Outperform at William Blair
09/11/20
Fly Intel: Top five analyst initiations
09/11/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/10/20 Cantor Fitzgerald
Prevail Therapeutics initiated with an Overweight at Cantor Fitzgerald
PRVL Prevail Therapeutics
$10.00 /

+0.25 (+2.56%)

PRVL Prevail Therapeutics
$10.00 /

+0.25 (+2.56%)

PRVL Prevail Therapeutics
$10.00 /

+0.25 (+2.56%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.